With its plant-derived cannabidiol Epidiolex set to be become the first FDA-approved drug for seizures associated with rare childhood epilepsy conditions, GW Pharmaceuticals PLC is also looking to other therapeutic spaces in which to test its cannabinoid product candidates, including autism and brain cancer, the UK-based group's CEO told Scrip.
Further in the future, plant-derived cannabinoid products could offer alternatives to opioids, without the accompanying abuse danger, Justin Gover said...








